Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(5 sites)
United States
Laura and Isaac Perlmutter Cancer Center at NYU Langone Health, New York, New York Herbert Irving Comprehensive Cancer Center, New York, New York Virginia Cancer Specialist (NEXT Oncology-Virginia), Fairfax, Virginia Australia
Blacktown Hospital, Blacktown, New South Wales Chris O'Brien Lifehouse, Camperdown, New South Wales